Microfluidics Engineer – Lab-on-a-Chip
Location: London
Vacancy Type: Permanent
Salary: Competitive / DOE
KEMIO is working with an early-stage biotechnology company developing a novel life science technology platform.
The team is small, ambitious and technically driven, bringing together biology, microfluidics, engineering and automation to develop a new platform with significant commercial potential.
As the technology progresses through development and validation, they are looking for a hands-on Microfluidics Engineer to take ownership of microfluidic device development and associated instrumentation.
The Role
This is a highly practical engineering role where you will take lab-on-a-chip devices from initial concept through design, manufacture, testing and iterative optimisation.
You will design and manufacture prototypes using SLA 3D printing, integrate the devices with custom electronics and instrumentation, test performance in the lab and use experimental and computational data to continually refine the system.
You’ll be joining a start-up environment where you’ll have significant technical ownership and be expected to get hands-on with the technology.
What You’ll Do
About You
You will ideally bring:
Particularly Valuable
Previous commercial product-development experience would be highly advantageous, particularly experience taking microfluidic or lab-on-a-chip technology beyond proof-of-concept towards a reliable, manufacturable product.
Experience gained within biotechnology, diagnostics, medical devices, analytical instrumentation, life science instrumentation or other microfluidics-focused industries would also be highly relevant.
The Opportunity
This is an opportunity to take genuine ownership of a core engineering technology within an early-stage biotech.
You’ll be able to design the device, manufacture it, integrate the electronics and instrumentation, test it in the lab and iterate the system until it performs as required — directly influencing the development of the technology as it progresses towards commercialisation.
Posted 2 Oct 2026